2003004512
10/02/03

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/018369 A3

(51) International Patent Classification[7]: C07K 7/06, A61K 38/08, A61P 31/12

(21) International Application Number: PCT/US01/26008

(22) International Filing Date: 31 August 2001 (31.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/229,398	31 August 2000 (31.08.2000)	US
60/277,641	21 March 2001 (21.03.2001)	US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BABINE, Robert, Edward** [US/US]; 19 Concetta Way, Franklin, MA 02038 (US). **CHEN, Shu, Hui** [US/US]; 13256 Snow Owl Drive, Carmel, IN 46033 (US). **LAMAR, Jason, Eric** [US/US]; 1240 North Broadway, Apartment 19, Indianapolis, IN 46202 (US). **SNYDER, Nancy, June** [US/US]; 3830 West 850 North, Lizton, IN 46149 (US). **SUN, Xicheng, David** [CN/US]; 923 Grays Peak Drive, Superior, CO 80027 (US). **TEBBE, Mark, Joseph** [US/DE]; Volksdorfer Weg 32, 22391 Hamburg (DE). **VICTOR, Frantz** [US/US]; 4855 North Tuxedo Street, Indianapolis, IN 46205 (US). **WANG, Q., May** [US/US]; 12345 Moon River Court, Indianapolis, IN 46236 (US). **YIP, Yvonne, Yee, Mai** [CN/US]; 1441 Badger Drive, Indianapolis, IN 46260 (US). **COLLADO, Ivan** [ES/ES]; C/Santa Barbara 21, 2C, 28220 Madrid (ES). **GARCIA-PAREDES, Cristina** [ES/ES]; C/Arroyo de la Elipa 1, 4 Drcha, 28017 Madrid (ES). **PARKER, Raymond, Samuel, III** [US/US]; 511 Hayfield Court, Doylestown, PA 18901 (US). **JIN, Ling** [CN/US]; 3750 Power Drive, Carmel, IN 46033 (US). **GUO, Deqi** [CA/US]; 5747 Aqua Marine Drive, Carmel, IN 46033 (US). **GLASS, John, Irvin** [US/US]; 625 Bryn Mawr Drive, Indianapolis, IN 46260 (US).

(74) Agents: **PALMBERG, Arleen** et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), DE (utility model), DK (utility model), DM, DZ, EC, EE (utility model), ES, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,*

[Continued on next page]

(54) Title: PEPTIDOMIMETIC PROTEASE INHIBITORS



(1)

(57) Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors (1), particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

WO 02/018369 A3

ACTION

162162

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:
— *with international search report*

(88) Date of publication of the international search report:
15 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.